CIK 0001613780 · Non-accelerated filer<br>Smaller reporting company
DBV Technologies S.A.
Sign in to watch- Ticker
- DBVTF
- Exchange
- Nasdaq, OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- France
- Entity type
- operating
- Phone
- 330155427878
- Business address
- 107 AVENUE DE LA REPUBLIQUE, CHATILLON, France
Securities
- DBVT American Depositary Shares Nasdaq
- DBVTF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-29 | Mohideen Pharis Chief Medical Officer | Sale | −464 | $2.70 | $1K | 144,531 |
| 2026-01-29 | Mohideen Pharis Chief Medical Officer | Sale | −534 | $4.86 | $3K | 144,995 |
| 2026-01-12 | BAKER BROS. ADVISORS LP Director | Option exercise · BS Warrant | −2,299,656 | 0 | ||
| 2026-01-12 | BAKER BROS. ADVISORS LP Director | Option exercise · BS Warrant | −25,005,240 | 0 | ||
| 2026-01-12 | BAKER BROS. ADVISORS LP Director | Option exercise · Second Pre-Funded Warrant | +2,299,656 | 2,299,656 | ||
| 2026-01-12 | BAKER BROS. ADVISORS LP Director | Option exercise · Second Pre-Funded Warrant | +25,005,240 | 25,005,240 | ||
| 2025-12-18 | EPIC Bpifrance Member of 10% owner group | Sale | −1,292,103 | $4.19 | $5.4M | 7,303,369 |
| 2025-12-17 | EPIC Bpifrance Member of 10% owner group | Sale | −2,036,990 | $4.84 | $9.9M | 8,635,472 |
| 2025-12-17 | EPIC Bpifrance Member of 10% owner group | Sale | −40,000 | $5.28 | $211K | 8,595,472 |
| 2025-11-21 | Mohideen Pharis Chief Medical Officer | Sale | −1,624 | $2.77 | $4K | 101,529 |
| 2025-11-21 | Mohideen Pharis Chief Medical Officer | Grant or award | +44,000 | 145,529 | ||
| 2025-11-21 | Mohideen Pharis Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +253,000 | 253,000 | ||
| 2025-11-21 | Trapp Kevin Michael Chief Commercial Officer | Grant or award | +55,000 | 55,000 | ||
| 2025-11-21 | Trapp Kevin Michael Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +316,250 | 316,250 | ||
| 2025-11-21 | Boucinha Virginie Chief Financial Officer | Grant or award | +32,000 | 70,000 | ||
| 2025-11-21 | Boucinha Virginie Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +192,000 | 192,000 | ||
| 2025-11-21 | Tasse Daniel CHIEF EXECUTIVE OFFICER | Grant or award · Employee Stock Option (right to buy) | +964,000 | 964,000 | ||
| 2025-11-20 | Mohideen Pharis Chief Medical Officer | Sale | −6,496 | $2.88 | $19K | 103,153 |
| 2025-07-29 | Mohideen Pharis Chief Medical Officer | Sale | −464 | $2.22 | $1K | 109,649 |
| 2025-05-22 | Mohideen Pharis Chief Medical Officer | Sale | −397 | $1.84 | $730 | 110,113 |
Page 1 of 4 · 70 trades